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Abstract 
Most patients with spread of large bowel cancer to other organs do not respond to immune 
therapy. We identified a rare gene mutation, termed 9p24.1 copy-number gain, in this 
otherwise incurable tumor that provoked an immune therapy response. We identified the 
chromosome 9p24.1 copy-number gain in a liver metastasis biopsy from a patient that had 
refractory disease to standard therapies, by gene-panel sequencing of DNA. Following 
immune checkpoint blockade with pembrolizumab (anti–PD-1), the patient experienced 
conversion of the tumor phenotype from one with epithelial features to that of an inflamed 
microenvironment, demonstrated by high-resolution RNA sequencing. Circulating tumor 
DNA disappeared over the first two weeks of therapy. As assessed by standard radiographic 
measurement, the patient had a partial response that was durable. This patient’s response may 
support the use of histology-agnostic immune checkpoint blockade in solid tumors that carry 
the rare 9p24.1 copy-number gain. 
  
Introduction 
The immune context of the tumor microenvironment (TME) determines the response 
to immune checkpoint blockade (ICB) in colorectal cancer (CRC; 1, 2). Favorable survival 
following ICB in metastatic disease from the minority of cases with primary CRC deficient in 
the DNA-mismatch repair (MMR) function is reflected by either high tumor mutational 
burden or positive microsatellite-instability (MSI) status (3, 4). Unlike for non-small-cell lung 
cancer (NSCLC), tumor-cell expression of the ligand of the programmed death receptor (PD-
1), PD-L1, has not been used as a predictive biomarker of ICB response in CRC. 
 Despite the extensive immune-cell infiltrate recruited by the malignant Reed-
Sternberg cells in classic Hodgkin’s lymphoma, the cytotoxic immune cells are anergic. This 
is frequently caused by Reed-Sternberg-cell copy-number gain (CNG) of chromosome 9p24.1, 
which includes loci for CD274, PDCD1LG2, and JAK2. This CNG leads to enhanced 
expression of PD-L1, the PD-1 ligand PD-L2, and Janus kinase-2 (JAK2) and thereby 
maintains Reed-Sternberg-cell survival signaling, unless the evasion of T-cell cytotoxicity is 
revoked by ICB (5-8). CNG of the 9p24.1 locus, associated with susceptibility to ICB, has 
been observed in rare lymphoma entities, and its prevalence in solid tumors is low, estimated 
to only 0.2% of CRC cases (9). 
The ‘Actionable Targets in Cancer Metastasis’ (MetAction) study (ClinicalTrials 
NCT02142036) established expedited and safe mutation profiling of an individual patients’ 
progressing metastatic cancer following failure of systemic therapies, in order to offer 
histology-agnostic, molecularly matched medication for end-stage cancer (10). The treatment-
refractory 9p24.1-CNG colon cancer case reported here illustrates the utility of this pipeline 
and further delineates the ICB response by diverse modalities. 
 
 
Materials and Methods 
Study procedures 
The study was approved by the Institutional Review Board, the Regional Committee 
for Medical and Health Research Ethics of South-East Norway (reference number, REK 
2013/2099), and the Norwegian Medicines Agency. It was performed in accordance with the 
Declaration of Helsinki. Written informed consent was required for participation. The study 
procedures and endpoints have been described previously (10) and are, together with details 
about the gene mutation profiling, provided in Supplementary Methods (10-12). 
DNA/RNA extracted from biopsy-sampled metastatic tissue and from a whole blood 
sample as germline control at enrollment was sequenced using the Ion Oncomine™ 
Comprehensive Assay v1 (Thermo Fisher Scientific). The median sequencing depth was 
~3000×, enabling calculation of the approximate mutant-allele fraction in heterogeneous 
tissue samples. The DNA sequence data was analyzed by the Torrent Suite™ software 
(Thermo Fisher Scientific); specifically, copy-number variants were detected in the copy-
number detection module of the Ion Reporter™ software (Thermo Fisher Scientific). The 
called gene variants were filtered prior to assessment and prioritization. The Molecular Tumor 
Board interpreted the findings with regard to the likelihood of involved tumor signaling 
activity, delivering conclusions that the following Clinical Tumor Board used to recommend 
potential systemic tumor-directed medication. 
Fluorescence in-situ hybridization analysis of the resected primary and locally 
recurrent tumors was performed to assess chromosome 9p copy-number, using a commercial 
probe pair that included a 350-kilobase 9p21.3-specific probe covering CDKN2A and 
CDKN2B, labeled with PlatinumBright™550, and a 440-kilobase 9q21-specific probe 
spanning from RH40366 to SHGC-82248, labeled with PlatinumBright™495 (both 
Kreatech™ probes KBI-10402). 
Cell-free DNA was extracted from plasma sampled at each CT examination. The 
quantitative digital PCR assay, capable of discriminating between the KRAS p.G12D and 
wildtype sequences, was performed on the Raindrop™ system (RainDance™ Technologies). 
RNA was extracted from liver metastasis biopsies sampled at study enrolment and 2 
weeks of treatment for high-resolution sequence analysis that yielded a minimum of ~35 
million reads per sample. Each transcript was quantified and compared for expression level in 
the two biopsy specimens. Differentially expressed genes were analyzed for significant 
biological functions and signaling pathways inherent in the tumor phenotype responses using 




Following conclusion of the diagnostic procedure, the patient had a baseline computed 
tomography (CT) examination and commenced treatment with pembrolizumab (2 mg/kg 
every 3 weeks). Evaluation CT examinations were undertaken every 9 weeks. Routine blood 





 In October 2015, a 51-year-old woman with an otherwise unremarkable medical 
background presented with anemia and was diagnosed with a conventional-type colon 
adenocarcinoma located in the hepatic flexure and extending into the right liver lobe. The 
tumor was positive for the KRAS p.G12D mutation and MSI markers and devoid of the MMR 
protein PMS2. The patient was referred to neoadjuvant oxaliplatin-based chemotherapy [the 
Nordic FLOX regimen (13)], but CT evaluation after 3 cycles revealed locally progressive 
disease. The patient underwent a right-sided hemicolectomy and in-continuity resection of the 
involved liver segments. Histological examination of the surgical specimen confirmed 
margin-negative ypT4bN0V0-stage disease. The patient was not offered adjuvant oncologic 
therapy. 
Repeat CT scanning 4 months after the surgical procedure showed a locally recurrent 
tumor comprising the duodenum and pancreas, and the patient proceeded directly to salvage 
surgery. The histological examination noted a positive margin towards the posterior 
abdominal wall and tumor infiltration in a portal vein. One month post-operatively the patient 
commenced a 5-week-long chemoradiotherapy regimen (delivered to the involved area of 
dissection). 
A repeat CT record 3 months after completion of the adjuvant treatment revealed one 
metastatic lesion in each liver lobe in addition to an enlarged portal hilum lymph node. The 
patient was assessed for palliative irinotecan-based chemotherapy [the Nordic FLIRI regimen 
(14)], but disease progression was noted after 4 cycles. Immune checkpoint inhibitors are not 
approved by Norwegian health authorities for treatment of advanced MSI-positive CRC 
within the public health services, thus, the patient was ineligible in routine clinical practice. In 
February 2017, she was enrolled in the MetAction study. 
 
Metastasis genome profiling 
Following study enrollment, ultrasound-guided core biopsies were taken from the 
metastatic lesion in the left liver lobe without procedure-induced complications. Tumor-cell 
content was 30% as assessed by tissue imprint. The DNA sequencing revealed point 
mutations commonly observed in CRC (APC p.R216X, KRAS p.G12D, and FBXW7 
p.R465H), each with approximately 30% mutant-allele fraction, in addition to an estimated 
≥4-fold relative 9p-CNG (Fig. 1A), confirmed by fluorescence in-situ hybridization (Fig. 1B). 
Acknowledging the approximations by applying the Oncomine™ Comprehensive Assay to 
estimate the tumor mutational burden, defined as the number per megabase of coding 
synonymous base substitutions and indel mutations, but excluding known driver mutations 
(15), only one of the identified mutations was eligible. This corresponded to a tumor 
mutational burden rate of 5, which is typical for MMR-proficient CRC (16). 
 
Clinical response 
Following tumor board consensus supporting treatment with a PD-1 inhibitor and 
patient’s commencement of pembrolizumab treatment, blood tests showed decline in tumor 
markers already at 2-3 weeks (Fig. 2A). The moderately elevated liver enzymes decreased 
over the entire treatment course; liver function markers as well as differential blood counts, 
electrolytes, and other renal function markers have all been within reference limits throughout 
therapy. The first CT evaluation after 3 treatment cycles revealed a partial response, 
according to the Response Evaluation Criteria in Solid Tumors v1.1, which remained 
consolidated at the 1-year treatment evaluation (Fig. 2B). The patient has been continuing the 
treatment for 20 months with ongoing partial response (by November 2018). 
 As shown by Supplementary Fig. S1, the patient experienced a rise in plasma free-T4 
and a corresponding fall in thyroid-stimulating hormone only 2-3 weeks after commencement 
of therapy. Grade 1 hyperthyroidism (by Common Terminology Criteria for Adverse Events 
v4.0) was evident when the patient started the third treatment cycle, whereas grade 2 
hypothyroidism was recorded at commencement of cycle 4. Since then, the patient has been 
on continuous medication with levothyroxine that has been dose-adjusted based on the 
continuous monitoring of plasma thyroid-stimulating hormone and free-T4. The patient has 
not reported other adverse events. 
Circulating tumor DNA (ctDNA) response 
Plasma analysis showed a decline in the KRAS mutant-allele fraction from 23% at 
baseline to 2.4% at 2 weeks of study treatment (Fig. 2C). A mutant-allele fraction of only 
0.1% was detected in the concurrent liver metastasis biopsy. Plasma specimens sampled at 
each of the CT evaluations were negative for KRAS p.G12D (Fig. 2C). 
 
Metastasis phenotype response 
The RNA transcript profile of the left liver lobe metastasis (the individual RNA 
sequence counts are provided in Supplementary Table S1) changed over the first 2 weeks of 
PD-1 blockade (Supplementary Table S2). Although expression of CD274 (PD-L1) and JAK2 
diminished, PDCD1LG2 (PD-L2) expression increased in the on-treatment biopsy 
(Supplementary Table S3). Among the most discriminating RNA profile-defined functions 
altered between the baseline and 2-week samples were activation of responses ascribed to 
immune-cell trafficking, lipid metabolism, and inflammation, whereas biological features 
related to epithelial neoplasia were inhibited (Fig. 3A and Supplementary Table S4). 
Moreover, profile-defined signaling pathways that were induced by pembrolizumab included 
activation of the liver-X/retinoid-X hormone receptor transcription factors (LXR/RXR) and 
acute-phase reaction with the complement system (Fig. 3B and Supplementary Table S5). An 
18-gene T-cell-inflamed expression profile that predicted response to pembrolizumab across 
multiple solid tumors has been reported (17). In our dataset, a majority of these interferon--
responsive genes were activated in the metastasis at 2 weeks of pembrolizumab treatment, 





We report a radiographically partial and durable response of advanced colon cancer on 
PD-1 blockade based on 9p24.1-CNG detected in a metastatic liver lesion. A decline in 
circulating routine tumor markers and the mutant KRAS DNA was observed already following 
the first therapy cycle, mirroring the conversion of the metastasis phenotype from epithelial 
features to characteristics of an inflamed TME. The response measured with each of diverse 
modalities was consistent with the MetAction diagnostic procedure concluding that the CNG 
of chromosome 9p24.1 represented the driver alteration. This cause of ICB susceptibility is 
rare in solid tumors and particularly in CRC (9). One other case of advanced 9p24.1-CNG 
colon adenocarcinoma treated with a PD-1 inhibitor has been reported (18). 
 The therapeutic response came with a common toxicity, a transient hyperthyroidism 
preceding hypothyroidism that was managed by hormone substitution. Patients with advanced 
NSCLC have better response and outcome measures to ICB if they developed thyroid 
dysfunction, which was an independent predictive factor (19, 20). This suggests a mechanistic 
connection between the thyroid hormone metabolism and ICB efficacy. In mice, the T4 
metabolite triiodothyronine stimulated tumor-antigen-presenting dendritic cells to impel 
interferon--mediated T-cell cytotoxicity (21). 
 Some studies have reported on the analysis of ctDNA to assess ICB efficacy in 
advanced cancer. A prospective pilot study of 10 patients with detectable ctDNA at 
commencement of therapy, including one MSI-positive CRC case, showed that complete 
ctDNA loss at the first treatment assessment (8 weeks) was associated with durable 
radiographic tumor response as well as long survival outcomes (22). An association between 
ctDNA and radiographic outcomes was also reported in 24 NSCLC cases (23). Our case 
showed 30% KRAS mutant-allele fraction in the baseline metastasis and only 0.1% at 2 weeks 
of treatment. The corresponding figures for ctDNA, 23% versus 2.4%, may reflect different 
methodological sensitivity or tumor load at other metastatic sites. Nevertheless, plasma KRAS 
p.G12D was undetectable from the first radiographic response evaluation at 9 weeks onwards. 
 The conversion of the liver metastasis phenotype following initiation of the PD-1 
inhibitor, as portrayed by the RNA sequence data, was perhaps the most intriguing 
observation. The interrelated phenotypes comprising CD274 (PD-L1) and JAK2 expression 
and sequences ascribed to intestinal epithelial neoplasia were attenuated, consistent with a 
rapid and substantial tumor-cell elimination. In contrast, expression of the chromosome 
9p24.1 partner PDCD1LG2 (PD-L2) was augmented in the 2-week biopsy sample. It has been 
proposed that PD-L2 positivity of tumor cells and TME cells predicts treatment response to 
PD-1 blockade through T-cell reactivity (24, 25). Hence, the heightened PD-L2 expression in 
the on-treatment metastasis specimen might have reflected activation of tumor-targeting 
immunity. 
 The computational RNA sequence analysis further revealed enrichment of 
pembrolizumab-induced functions and signaling pathways with designations such as immune-
cell trafficking but also inflammation, acute-phase response, and complement system activity. 
The complement complex belongs to the rapidly responding innate immunity and exerts 
opposing effects within tumor-antigen presentation and T-cell-mediated cytotoxicity on the 
one side and TME activation of tumor-supportive systemic inflammation on the other (26). 
However, the data also supported pembrolizumab-induced activity of interferon--responsive 
genes involved in tumor-eliminating T-cell effects (17). The patient has had no clinical or 
biochemical evidence of systemic inflammation during the treatment course. Expression of 
the interferon--responsive IDO1, encoding the essential indoleamine 2,3-dioxygenase-1 of 
various TME-cell types that participate in immune tolerance to tumor antigens (27), was 
repressed at 2 weeks of ICB. Noting the failure or termination of clinical trials adding an 
indoleamine 2,3-dioxygenase-1 inhibitor to PD-1 blockade, it may be that this particular 
combination is mechanistically redundant. 
 The RNA transcript profile also revealed a possible role of lipid metabolism and 
particularly LXR/RXR activity in the patient’s metastatic cancer on ICB response. In mouse 
models, administration of an LXR agonist reduced the numbers of systemic and tumor-
infiltrating myeloid-derived suppressor-cells (an innate immune-cell population), which 
evoked T-cell cytotoxicity and restrained tumor growth; similar effects on peripheral blood 
myeloid-derived suppressor-cells and cytotoxic T-cells were observed in patients (28). It has 
been known for almost three decades that LXR/RXR function as co-regulators of thyroid 
hormone receptor-mediated transcription (29). However, in our patient’s case, it is not clear 
how the initial hyperthyroidism and the concurrent ICB-induced LXR/RXR activity in the 
metastatic cancer were mechanistically interrelated. 
 The patient described here, presenting to the MetAction study with metastatic colon 
cancer refractory to all standard therapies, has experienced durable, near-complete 
radiographic tumor regression following administration of pembrolizumab based on the 
detection of 9p24.1-CNG in a liver metastasis. Our experience may support the use of PD-1 
blockade in histology-agnostic cases with 9p24.1-CNG. 
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Figure 1. 
Chromosome (Chr.) 9p copy-number gain. Panel A shows the genes within the 9p amplicon, 
as covered by the Oncomine™ Comprehensive Assay and each with its relative copy-number 
gain, identified in the liver metastasis specimen sampled at study enrolment. Panel B shows 
nuclei from the primary tumor specimen with 9p21.3 copy-number gain [9p21.3 (red signals) 
to 9q21 (green signals) ratio of 3.4 from the average copy numbers of 4.7 for 9p21.3 and 1.4 
for 9q21], as assessed by fluorescence in-situ hybridization. 
Figure 2. 
Tumor response to the study treatment. Panel A shows amounts of circulating tumor markers 
over the treatment course. The start of a new treatment cycle corresponds to the given week 
numbers. Panel B shows one transverse-view image from each of portovenous-phase contrast-
enhanced computed tomographic scans of the abdomen recorded before commencement of 
the study treatment (top panel), at the first evaluation (middle panel), and at the 1-year 
evaluation (bottom panel). Longest cross-sectional perpendicular measures at these points 
were for the right liver lobe lesion: 120 mm  100 mm, 56 mm  46 mm, and 25 mm  15 
mm; for the left liver lobe lesion: 125 mm  66 mm, 79 mm  37 mm, and 52 mm  22 mm; 
for the short axis of the portal hilum lymph node (not depicted on the selected images): 26 
mm, 22 mm, and 13 mm. Panel C shows the circulating amounts of the mutant KRAS relative 
to the wildtype variant over the treatment course. The inserted histograms show the 
quantification by digital PCR of the two KRAS alleles before the start (top panel) and at 2 
weeks (middle panel) and 9 weeks (bottom panel) of the study treatment. 
Figure 3. 
Phenotypic response to the immune checkpoint blockade. Panel A shows annotated functions, 
as defined by the Ingenuity® Pathway Analysis software, based on differentially expressed 
genes (n = 4,168) in the 2-week versus baseline biopsy specimen from the left liver lobe 
metastasis, ranked by z-score. The resulting functions (Supplementary Table S4) were filtered 
according to the following criteria: z-score higher than 3.4 or lower than –1.6, p < 310-6, and 
removal of redundant functions. Panel B shows the software’s signaling pathway annotation 
of the input genes, ranked by p-value and following removal of redundant pathways (from 
Supplementary Table S5); patterned bars, no z-score. Panel C shows log2 fold-change (FC) 
expression of 18 interferon--responsive genes, which define a profile predictive of response 
to immune checkpoint blockade (17), in the 2-week versus baseline biopsy specimen. 
